Table 2.
2020 | 2019 | 2018 | |
---|---|---|---|
Admitted N (%) | 15 (52) | 29 (62) | 29 (69) |
| |||
Treatment N (%) | |||
Cef/Vanc | 13 (45) | 25 (53) | 28 (64) |
Ofloxacin | 14 (48) | 17 (36) | 7 (16) |
Brolene/PHMB | 1 (3) | 3 (6) | 1 (2) |
Anti viral | 0 | 5 (11) | 5 (11) |
Anti fungal | 1 (3) | 2 (4) | 1 (2) |
Not recorded | 0 | 0 | 3 (7) |
Treatment, all patients receiving described treatment, including combination therapy. Cef/Vanc, ceftazidime/vancomycin; PHMB, polyhexamethylene biguanide; others, antifungal and antiviral therapy.